Neurophysiological Diagnosis for ICU Septic Shock Patients (EDX)

October 3, 2019 updated by: CAROLINE ATTWELL, Centre Hospitalier Universitaire Vaudois

Early Electromyographic Evaluation of the ICU-acquired Weakness in Septic Shock Patients Ventilated Longer Than 72 Hours: Neurophysiological Study

Patients hospitalized in the Intensive Care Unit (ICU) are at risk for developing severe disabilities, physical or cognitive. In particular, ICU-acquired weakness is frequent. The causes of this weakness are multiple and the physiopathology is still not fully understood. Immobilization in bed and sepsis are known risk factors.

ICU-acquired weakness has been associated with prolonged mechanical ventilation duration, and increased in ICU and hospital length of stay. It has also been associated with significant decrease in functional capacity and with higher mortality. An early screening using a specific diagnostic protocol could help improving the management of patients suffering from ICU acquired weakness.

The aim of this study is to early detect ICU acquired weakness in patients suffering from septic shock and ventilated for more than 72 hours.

Study Overview

Status

Unknown

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients admitted to the ICU with a septic shock and ventilated for more than 72 hours.

Description

Inclusion Criteria:

• Patients admitted to the ICU with a septic shock and ventilated for more than 72 hours.

Exclusion Criteria:

  • Hospitalization for more than 7 days before intubation.
  • Functional disability at admission of ≥4 (Requires constant nursing care and attention, bedridden, incontinent) in the Modified Rankin Scale.
  • Lower limb disorders precluding nerve conduction studies (NCV) and electromyography (EMG), such as clinical edema of the lower limbs, or fractures, amputation, and plaster casts of the lower limbs.
  • Evidence of altered neuromuscular transmission at repetitive stimulation test either caused by neuromuscular blocking agents or disease.
  • Burn patients admitted to ICU.
  • Patient requesting withdrawal of therapies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Presence of ICU-acquired weakness in septic shock patients ventilated for more than 72 hours.
Time Frame: 72 hours
Medical Research Council strength scale
72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ICU length of stay
Time Frame: Up to 6 months
Up to 6 months
Hospital length of stay
Time Frame: Up to 6 months
Up to 6 months
Discharge destination
Time Frame: At discharge from hospital, up to 6 months
At discharge from hospital, up to 6 months
Length of ventilatory support
Time Frame: At extubation, up to 6 months
At extubation, up to 6 months
Extubation failure rate
Time Frame: up to 72 hours, after first extubation
Patients requiring reintubation 72 hours after failed first extubation
up to 72 hours, after first extubation
Time elapsed between endotracheal intubation and first out-of-bed mobilization
Time Frame: up to 6 months, at first out-of-bed mobilization
up to 6 months, at first out-of-bed mobilization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Karin Diserens, PD-MER, NRA Unit. CHUV.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 23, 2019

Primary Completion (ANTICIPATED)

October 31, 2019

Study Completion (ANTICIPATED)

December 31, 2019

Study Registration Dates

First Submitted

December 12, 2018

First Submitted That Met QC Criteria

January 11, 2019

First Posted (ACTUAL)

January 14, 2019

Study Record Updates

Last Update Posted (ACTUAL)

October 4, 2019

Last Update Submitted That Met QC Criteria

October 3, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NRA-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ICU Acquired Weakness

Clinical Trials on Nerve conduction study

3
Subscribe